ABBVPharmacyclics LLC.Finished
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Follicular Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 445 (final count)
- Started
- Jan 23, 2017
- Main results expected
- Feb 21, 2024
- Fully finished
- Jun 9, 2025
- Results posted
- Mar 17, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) as Assessed by Investigator
Measured over: Primary Analysis cut-off; median overall follow-up of 53.75 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT02947347 · record last updated 2026-03-17 · checked 2026-11-09 15:47 UTC